PCM
NGNE icon

Prelude Capital Management’s Neurogene NGNE Stock Holding History

Prelude Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-68
Closed -$18K – 1704
2016
Q3 		$18K Buy
+68
New +$13.7K ﹤0.01% 1356

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Prelude Capital Management's NGNE Position: Q4 2016 in Review

Prelude Capital Management sold out of Neurogene (NGNE) in Q4 2016, closing a stake of 68 shares — an estimated $18K sold.

Prelude Capital Management first reported a position in NGNE in Q3 2016 and held it in 1 quarter. The position peaked at $18K in Q3 2016. 49 funds tracked by Wall St. Rank hold NGNE as of Q4 2016.

  • Prelude Capital Management reported no remaining Neurogene position as of Q4 2016 after selling out during the quarter.
  • Prelude Capital Management sold 68 Neurogene shares in Q4 2016, an estimated $18K.
  • Prelude Capital Management first reported a position in Neurogene in Q3 2016 and held it in 1 quarter.
  • Prelude Capital Management's Neurogene position peaked at $18K in Q3 2016.
  • 49 funds tracked by Wall St. Rank held Neurogene as of Q4 2016.

Based on Prelude Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.